Cheryl Allen, BS Pharm, MBA, founding partner, highlights the coming year's focus on navigating an evolving regulatory ...

At a time when investors are questioning the sustainability of pharmaceutical business models, reliable execution has become ...

Modern PBMs, or PBM-like functions, should operate with full line-of-sight to net price and patient outcomes. Full ...

One of which revolved around “Optimizing GTN Strategy—Balancing Channel Economics and Market Access,” led by Lannett ...

Although he typically revises his macro framework only once every decade or more, Roth explained that the current environment ...

In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.

That era is ending. Policy reform, economic pressure, and patient empowerment have fractured that reality into three distinct ...

Point-of-care engagement is essential for converting investments in payer negotiations and copay programs into prescriptions.

The adoption of biosimilars is increasing, with a predicted global market CAGR of 18%, though uptake varies by market and is influenced by factors like rebate schemes and patent litigation.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how ...

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...